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Objective: To examine the long-term cardiovascular consequences of angina in a large epidemiological study.
Design: Prospective cohort study conducted between 1972 and 1976 with 20 years of follow-up (the
Renfrew–Paisley Study).
Setting: Renfrew and Paisley, West Scotland, UK.
Participants: 7048 men and 8354 women aged 45–64 years who underwent comprehensive cardiovascular
screening at baseline, including the Rose Angina Questionnaire and electrocardiography (ECG).
Main outcome measures: All deaths and hospitalisations for cardiovascular reasons occurring over the
subsequent 20 years, according to the baseline Rose angina score and baseline ECG.
Results: At baseline, 669 (9.5%) men and 799 (9.6%) women had angina on Rose Angina Questionnaire.
All-cause mortality for those with Rose angina was 67.7% in men and 43.3% in women at 20 years
compared with 45.4% and 30.4%, respectively, in those without angina (p,0.001). Values are expressed
as hazards ratio (HR) (95% confidence interval (CI). In a multivariate analysis, men with Rose angina had
an increased risk of cardiovascular death or hospitalisation (1.49 (1.33 to 1.66), myocardial infarction
(1.63 (1.41 to 1.85)) or heart failure (1.54 (1.13 to 2.10)) compared with men without angina. The
corresponding HR (95% CI) for women were 1.38 (1.23 to 1.55), 1.56 (1.31 to 1.85) and 1.92 (1.44 to
2.56). An abnormality on the electrocardiogram (ECG) increased risk further, and both angina and an
abnormality on the ECG increased risk most of all compared with those with neither angina nor ischaemic
changes on the ECG. Compared with men, women with Rose angina were less likely to have a
cardiovascular event (0.54 (0.46 to 0.64)) or myocardial infarction (0.44 (0.35 to 0.56)), although there
was no sex difference in the risk of stroke (1.11 (0.75 to 1.65)), atrial fibrillation (0.84 (0.38 to 1.87)) or
heart failure (0.79 (0.51 to 1.21)).
Conclusions: Angina in middle age substantially increases the risk of death, myocardial infarction, heart
failure and other cardiovascular events.
A
lthough the incidence of myocardial infarction is
decreasing, the incidence of angina pectoris is increas-
ing.1 Despite angina being the most common manifes-
tation of coronary heart disease and the most common symp-
tomatic cardiac condition, relatively little is known about the
long-term natural history of angina at a population level,
especially in women.2–5 Most existing population-based studies
have mainly or exclusively reported outcomes in men.6–9 Only a
few described prognosis in women, but have not usually
compared it with men in the same population.10 11 Most
existing studies that have reported clinical outcomes have
focused on death, myocardial infarction or both.2–4 6–8 Patients
with angina are likely to be at increased risk of other
complications of coronary heart disease (eg, heart failure) or
non-cardiac vascular events (eg, stroke).9 Similarly, the true
lifetime burden of angina is reflected not only in fatal but also
in non-fatal events, especially those leading to hospital
admission. Consequently, the aim of this study was to examine
the long-term population risk of fatal and non-fatal cardio-
vascular events in both men and women with angina, during
20-year follow-up of 15 402 initially middle-aged people (8354
women) who were first screened between 1972 and 1976.12–14
METHODS
Sample and baseline data
Details of the Renfrew–Paisley study have been published
previously.15 In brief, between 1972 and 1976, 7048 men and
8354 women aged 45–64 years, living in the industrialised
towns of Renfrew and Paisley, western Scotland, UK,
participated in this epidemiological study.12 These people
represented 80% of the target population residing in these
two towns. Each person’s demographic profile and cardio-
respiratory health status were documented.12
Rose angina criteria
The standard Rose angina classification was used.16 The
validity of the Rose Angina Questionnaire has been tested in
studies comparing it to a clinical diagnosis of angina,
abnormality on the ECG, thallium scanning and as a
predictor of mortality due to coronary artery disease.17–21 In
this classification, grade I angina is defined as pain or
discomfort when walking uphill or hurrying. Angina is
classified as grade II when the person reports chest pain or
discomfort also when walking at an ordinary pace on level
ground. Angina is further classified as ‘‘definite’’ if, in
addition, the pain is sited in the sternum or the left chest and
arm, causes the person to stop or slow down, and resolves
within 10 min of the person stopping or slowing down. If
these additional criteria are not satisfied, angina is classified
as ‘‘possible’’. For the purpose of this study, angina was
defined as Rose grade I and II ‘‘definite’’ angina and was not
confirmed by further investigation or evaluation. Possible
Abbreviations: ECG, electrocardiography; ICD9, International
classification of diseases, 9th revision
myocardial infarction (identified by a separate question on
the Rose Questionnaire, as having ever experienced a severe
pain across the front of the chest, lasting for >30 min) was
noted.
Criteria for ischaemic changes on the ECG
A six-lead ECG was also obtained and coded.12 The following
Minnesota codes were considered to represent ECG evidence
of ischaemia: 1.1–1.3, Q waves; 4.1–4.3, ST junction and
segment depression; 5.1–5.3, T wave abnormalities; and 7.1,
left bundle branch block.22
Study follow-up
Electronic linkage to hospital and death records is possible
for all residents of Scotland, as previously reported.13–15 We
followed up all people until date of death or censorship. Date
of censorship was 20 years from the date of each person’s
initial screening visit. The Scottish Morbidity Record Scheme
was used to retrieve details of all discharges from hospital
(according to the eighth (a small number of initial episodes)
and ninth revisions of the World Health Organization
International classification of diseases (ICD9)) during the
20 years after initial screening.23 We noted the occurrence
and timing of admissions for acute myocardial infarction
(410), coronary heart disease (410–414), heart failure (425.4,
425.5, 428 and 402), thromboembolic disease (415 and
451.1), aortic aneurysm (441), atrial fibrillation (427.3) and
cerebrovascular incidents (430–438). These diagnoses, in
combination with several other less commonly recorded
diagnoses, are collectively called cardiovascular hospitalisa-
tions. Audits have shown that these data are about 90%
accurate in identifying the correct discharge diagnosis.24
Deaths and their certified cause were obtained from the
National Health Service Central Register for the same period.
We excluded 17 (0.1%) patients who emigrated, as their vital
status was unknown.
Statistical analysis
Data on men and women were analysed separately and
compared. As an abnormality on the ECG is recognised to be
of prognostic importance, people with ischaemic changes on
ECGs were analysed separately from those without ischaemic
changes on ECGs, and the groups were compared.25
Categorical variables were compared using the x2 test and
continuous variables using Student’s t test. We used Cox’s
proportional hazards regression models to examine the
relationship between Rose-positive angina (with and without
ischaemic changes on an ECG) and outcome. We adjusted for
age, blood pressure, cholesterol, history of diabetes, number
of cigarettes smoked per day (with an additional 0/1 variable
for ex-smoker), Rose myocardial infarction, adjusted forced
expiratory volume in one second and social class. All data
were analysed using SPSS V.11.5.
RESULTS
Prevalence of angina
At baseline screening, 669 (9.5%) men and 799 (9.6%)
women had Rose-positive angina. Of these, 22.7% of men and
14.8% of women had an ischaemic change on the ECG.
Conversely, 697 (9.9%) men and 712 (8.5%) women had an
ischaemic change on the ECG. Of these, 21.8% of men and
16.6% of women had angina.
Baseline characteristics according to the presence of
angina at baseline
Compared with people with no angina and no ischaemic
changes on the ECG, those with angina or ischaemic changes
on the ECG were older and more likely to have cardiovascular
risk factors or prior cardiovascular disease (these findings
were generally more marked for people with an abnormality
on the ECG; table 1). This gradient was also seen for
pulmonary disease.
Table 1 Baseline characteristics of the Renfrew–Paisley cohort, according to the presence of angina and ischaemic changes on
the electrocardiogram at baseline
Men Women
No angina,
no ischaemic
changes
on ECG
(n = 5834)
No angina,
ischaemic
changes
on ECG
(n = 545)
Angina,
no ischaemic
changes
on ECG
(n = 517)
Angina,
ischaemic
changes
on ECG
(n = 152)
No angina,
no ischaemic
changes
on ECG
(n = 6961)
No angina,
ischaemic
changes
on ECG
(n = 594)
Angina,
no ischaemic
changes
on ECG
(n = 681)
Angina,
ischaemic
changes
on ECG
(n = 118)
Age (years) 54 (6) 56 (6)*** 56 (5)*** 57 (5)*** 54 (6) 56 (5)*** 55 (6)*** 58 (5)***
History of stroke` 55 (0.9) 19 (3.5)*** 13 (2.5)** 6 (4.0)** 53 (0.8) 30 (5.1)*** 12 (1.8)** 9 (7.6)***
Rose myocardial
infarction`
380 (6.5) 98 (18.0)*** 136 (26.3)*** 74 (48.7)*** 296 (4.3) 58 (9.8)*** 121 (17.8)*** 29 (24.6)***
Current or
ex-smoker`
4811 (82.5) 462 (84.8) 463 (89.6)*** 131 (86.2) 3786 (54.4) 284 (47.8)** 387 (56.8) 69 (58.5)
Diabetes` 67 (1.1) 10 (1.6) 9 (1.7) 4 (2.6) 70 (1.0) 17 (2.9)*** 8 (1.2) 5 (4.2)**
Blood glucose
(mmol/l)
5.1 (1.6) 5.5 (2.1)*** 5.1 (1.6) 5.2 (1.3) 5.0 (1.3) 5.4 (2.2)** 5.1 (1.3) 5.6 (2.3)*
Plasma cholesterol
(mmol/l)
5.9 (1.0) 5.9 (1.0)* 5.9 (1.0) 6.0 (1.0)* 6.4 (1.1) 6.5 (1.1) 6.4 (1.1) 6.6 (1.2)*
Body mass index
(kg/m2)
25.8 (3.4) 26.5 (3.4)*** 25.9 (3.6) 26.3 (3.6) 25.6 (4.4) 26.7 (4.9)*** 26.9 (4.9)*** 27.0 (5.5)**
Systolic BP
(mm Hg)
147 (22) 159 (26)*** 150 (24)* 154 (¡25)** 149 (24) 163 (29)*** 153 (27)*** 165 (31)***
Diastolic BP
(mm Hg)
85 (13) 91 (15)*** 86 (14) 89 (16)** 84 (13) 90 (15)*** 87 (14)*** 92 (17)***
Cardiothoracic ratio 0.46 (0.05) 0.49 (0.05)*** 0.47 (0.05)* 0.50 (0.05)*** 0.48 (0.05) 0.50 (0.06)*** 0.49 (0.05)*** 0.52 (0.06)***
Adjusted FEV1 (%) 90.2 (21.6) 85.4 (21.8)*** 78.7 (25.7)*** 79.9 (25.1)*** 93.7 (22.7) 88.8 (23.6)*** 84.8 (25.6)*** 83.5 (26.2)***
Chronic bronchitis` 247 (4.2) 38 (7.0)** 100 (19.3)*** 27 (17.8)*** 207 (3.0) 32 (5.4)** 96 (14.1)*** 9 (7.6)*
Atrial fibrillation
on ECG`
35 (0.6) 10 (1.8)** 5 (1.0) 3 (2.0) 20 (0.3) 14 (2.4)*** 6 (0.9)* 7 (5.9)***
BP, blood pressure; ECG, electrocardiogram; FEV1, forced expiratory volume in one second.
*p,0.05; **p,0.01; ***p,0.001 for each group compared with the group having no angina or no ischaemic changes on ECG.
Values are mean (SD).
`Values are n (%).
Compared with women, men with angina were signifi-
cantly more likely to be current or ex-smokers (p,0.001),
and to have a lower forced expiratory volume in one second
(p,0.001) and more chronic bronchitis (p = 0.002). Men
were also more likely to have a history of Rose-myocardial
infarction (p,0.001). Conversely, women had a higher total
cholesterol (p,0.001), systolic blood pressure (p = 0.005)
and cardiothoracic ratio (p,0.001).
Survival over 20 years follow-up
A larger proportion of men than women died over the 20-year
follow-up period, irrespective of whether or not they had
angina (fig 1; table 2). Men and women with angina were
more likely to die than those without angina. In all, 67.7% of
men with angina died over the 20 years of follow-up
compared with 45.4% of those without angina (p,0.001).
The corresponding figures for women were 43.3% and 30.4%
(p,0.001). Both angina and ischaemic changes on ECG were
associated with increased risk. An ischaemic change on ECG
was associated with a greater risk than that seen with angina
alone (ie, when there were no ischaemic changes on ECG).
Patients with angina and an abnormality on the ECG had
the highest risk for death. Angina was associated with an
increase in the adjusted risk for death from all causes,
cardiovascular causes and, especially, coronary causes. The
adjusted hazard ratio (HR; 95% (CI)) confidence interval (CI)
for death from any cause was 1.30 (1.17 to 1.44) in men and
1.20 (1.07 to 1.35) in women (compared with those without
angina), whereas the HR for death from a coronary cause was
1.71 (1.47 to 2.00) in men and 1.36 (1.11 to 1.67) in women.
Both angina and an ischaemic change on ECG were
separately associated with increased risk, although the risk
associated with an abnormality on the ECG was greater. Men
with angina but no ECG changes had a 54% increase in the
adjusted RR for dying from coronary heart disease (compared
with people with neither angina nor ECG changes), whereas
women had a 23% increased risk. The corresponding increase
in people with an abnormality on the ECG but no angina was
97% in men and 78% in women.
The increase in RR was greatest in patients with angina
and an abnormality on the ECG, where men had a nearly
fourfold and women had a nearly threefold increased risk of
death from coronary heart disease compared with that in
people without angina or an ischaemic change on ECG.
Hospitalisation from cardiovascular causes
Men and women with angina were more likely than those
without angina to experience a cardiovascular hospitalisation
(table 3). In all, 43.5% of men with angina experienced such
an event over the 20 years of follow-up compared with 32.7%
of those without angina (p,0.001). The corresponding
figures for women were 37.4% and 24.6% (p,0.001). The
adjusted RR for admission to hospital for a cardiovascular
reason was increased to a similar extent as the risk for death
Figure 1 Age-adjusted Cox’s survival curves for all-cause death,
according to the presence of angina or ischaemic changes on an
electrocardiogram (ECG) in (A) men and (B) women.
Figure 2 Age-adjusted Cox’s survival curves for cardiovascular death
or hospital admission, according to the presence of angina or ischaemic
changes on electrocardiogram (ECG) in (A) men and (B) women.
from a cardiovascular cause. As with death, the increased risk
of a major coronary event was even greater.
As with death alone, the risk for hospital admission for a
cardiovascular reason was increased by both angina and an
ischaemic change on ECG, separately. Unlike death, the
increase in risk was not substantially greater with an
abnormality on the ECG than with angina. However, as with
death, the greatest risk was seen in patients with angina and
an abnormality on the ECG. In these patients, the relative
risk of a cardiovascular hospitalisation was increased 2.4-fold
in men and 2.5-fold in women (compared with people with
neither angina nor an ischaemic change on ECG).
Angina, an ischaemic change on ECG and, especially, both
together, were associated with an increased risk for hospi-
talisation due to heart failure and stroke (angina alone did
not increase the risk for stroke in men).
Death or hospitalisation from cardiovascular causes
Patients with angina were more likely to experience a major
non-fatal or fatal cardiovascular event than those without
angina (fig 2; table 4). In all, 61.6% of men with angina
experienced such an event over the 20 years of follow-up
compared with 43.4% of those without angina (p,0.001).
The corresponding figures for women were 45.9% and 30.9%
(p,0.001). The adjusted RR for a major fatal or non-fatal
cardiovascular event was increased to the same extent as the
risk for death from a cardiovascular cause. As with death, the
increased risk of a major coronary event was even greater.
Men with angina had an increased risk of cardiovascular
death or hospitalisation (HR 1.49, 95% CI 1.33 to 1.66),
myocardial infarction (HR 1.63, 95% CI 1.41 to 1.89) and
heart failure (HR 1.54, 95% CI 1.13 to 2.10) compared with
men without angina. The corresponding HRs (95% CI) for
women were 1.38 (1.23 to 1.55), 1.56 (1.31 to 1.85) and 1.92
(1.44 to 2.56).
As with death alone, the risk for either a major fatal or
non-fatal event was increased by both angina and an
ischaemic change on ECG separately. The increase in risk
was greater with an abnormality on the ECG. However, even
those with angina, but without an abnormality on the ECG,
had substantial and significant increases in risk of cardio-
vascular and coronary events compared with those with
neither angina nor ischaemic changes on ECG.
All of these risks were increased in patients with angina
and an abnormality on the ECG, in whom the RR of a major
fatal or non-fatal coronary event was increased fourfold in
men and threefold in women (compared with people with
neither angina nor an ischaemic change on ECG).
Examination of composite fatal and non-fatal outcomes
also showed that angina, an ischaemic change on ECG and,
especially, both, were associated with an increased risk of
death or hospitalisation due to heart failure and stroke
(angina alone did not increase the risk for stroke in men).
Table 2 Cause of death over 20 years according to the presence of angina and ischaemic change on electrocardiogram at
baseline
Men Women
No angina,
no ischaemic
changes
on ECG
(n = 5834)
No angina,
ischaemic
changes
on ECG
(n = 545)
Angina,
no ischaemic
changes
on ECG
(n = 517)
Angina,
ischaemic
changes
on ECG
(n = 152)
No angina,
no ischaemic
changes
on ECG
(n = 6961)
No angina,
ischaemic
changes
on ECG
(n = 594)
Angina,
no ischaemic
changes
on ECG
(n = 681)
Angina,
ischaemic
changes
on ECG
(n = 118)
Any cause 2537 (43.5) 358 (65.7)*** 325 (62.9)*** 128 (84.2)*** 2012 (28.9) 285 (48.0)*** 268 (39.4)*** 78 (66.1)***
1.00 1.53 (1.37 to
1.71)
1.18 (1.04 to
1.33)
2.47 (2.06 to
2.97)
1.00 1.48 (1.30 to
1.68)
1.15 (1.01 to
1.31)
1.99 (1.58 to
2.51)
Any
cardiovascular
cause
1249 (21.4) 246 (45.1)*** 179 (34.6)*** 96 (63.2)*** 916 (13.2) 190 (32.0)*** 141 (20.7)*** 58 (49.2)***
1.00 2.02 (1.75 to
2.32)
1.35 (1.14 to
1.59)
3.50 (2.81 to
4.34)
1.00 1.90 (1.61 to
2.23)
1.25 (1.04 to
1.50)
2.71 (2.06 to
3.58)
Coronary heart
disease
889 (15.2) 170 (31.2)*** 145 (28.0)*** 77 (50.7)*** 543 (7.8) 104 (17.5)*** 83 (12.2)*** 38 (32.2)***
1.00 1.97 (1.67 to
2.34)
1.54 (1.28 to
1.84)
3.82 (2.99 to
4.88)
1.00 1.78 (1.43 to
2.21)
1.23 (0.97 to
1.57)
2.92 (2.07 to
4.18)
Myocardial
infarction
730 (12.5) 143 (26.2)*** 112 (21.7)*** 65 (42.8)*** 462 (6.6) 82 (13.8)*** 73 (10.7)*** 33 (28.0)***
1.00 1.99 (1.65 to
2.39)
1.44 (1.17 to
1.77)
3.84 (2.94 to
5.02)
1.00 1.64 (1.29 to
2.10)
1.28 (0.99 to
1.65)
2.98 (2.05 to
4.32)
Heart failure 34 (0.6) 7 (1.3) 5 (1.0) 2 (1.3) 26 (0.4) 10 (1.7)*** 6 (0.9) 3 (2.5)*
1.00 2.56 (1.11 to
5.91)
1.67 (0.63 to
4.42)
3.72 (0.86 to
16.13)
1.00 3.55 (1.66 to
7.58)
1.82 (0.73 to
4.52)
4.68 (1.32 to
16.52)
Atrial fibrillation 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 3 (0.4)** 0 (0)
1.00 — — — 1.00 — — —
Stroke 232 (4.0) 48 (8.8)*** 14 (2.5) 8 (5.3) 277 (4.0) 58 (9.8)*** 38 (5.6)* 14 (11.9)***
1.00 1.99 (1.45 to
2.75)
0.56 (0.32 to
0.97)
1.60 (0.78 to
3.29)
1.00 1.86 (1.39 to
2.50)
1.17 (0.83 to
1.65)
2.25 (1.29 to
3.92)
Aortic aneurysm 26 (0.4) 5 (0.9) 2 (0.4) 1 (0.7) 7 (0.1) 0 (0) 1 (0.1) 0 (0)
1.00 1.89 (0.71 to
5.04)
0.69 (0.16 to
3.02)
2.12 (0.27 to
16.40)
1.00 — 1.19 (0.14 to
10.03)
—
Venous
thromboembolism
17 (0.3) 2 (0.4) 2 (0.4) 1 (0.7) 12 (0.2) 4 (0.7)* 1 (0.1) 0 (0)
1.00 1.47 (0.33 to
6.51)
1.34 (0.30 to
6.06)
3.51 (0.43 to
28.88)
1.00 2.49 (0.76 to
8.19)
— —
ECG, electrocardiogram.
Values are n (%) or adjusted HR (95% CI).
*p,0.05; **p,0.01; ***p,0.001 for the proportion of deaths in each group compared with the group with no angina and no ischaemic changes on ECG.
Outcomes in men compared with those in women
The adjusted HR (95% CI) for death from any cause in
women compared with that for men was 0.52 (0.44 to 0.61;
p,0.001; table 5). Even after adjusting for the powerful effect
of an ischaemic change on ECG (which was more commonly
found in men), women had less than half the risk in men of
any adverse cardiovascular outcome. However, this difference
was mainly explained by a lower risk of coronary events; the
risk of stroke and heart failure was not lower in women.
DISCUSSION
This population-based study describes, in a more complete
way than previous studies, the mortality and morbidity
burden associated with angina over a long period of follow-
up. In particular, fatal and non-fatal outcomes are described
in a large cohort of women who have generally been excluded
from previous epidemiological studies on angina.
Although angina is suggested to be associated with a
relatively good prognosis, the present analysis clearly shows
otherwise.26 Consideration of only fatal outcomes under-
estimates the adverse prognostic effect of angina.9 27 Whereas
about 40% of men and 25% of women reporting this
symptom in middle age died from a cardiovascular cause,
almost half of the women and two thirds of the men went on
to experience a major fatal or non-fatal cardiovascular event
over the next two decades.
Our findings in men closely support those of previous
studies such as the Reykjavik Study,7 the Goteborg Primary
Prevention Study8 and the British Regional Heart Study.9 We
found that women had a better prognosis than men, as noted
in the few prior studies to include both sexes.3 5 This was
especially true for coronary events (both fatal and non-fatal).
Although men had a greater prevalence of certain adverse
coronary prognostic factors (especially ECG evidence of
ischaemia and infarction), women remained at lower risk
after adjusting for these differences. Interestingly, however,
women were less protected from non-coronary cardiovascular
events including stroke, heart failure and atrial fibrillation.
We do not know of any other reports of this discrepancy.
Consequently, although women had only a 1 in 5 twenty-year
risk of fatal or non-fatal myocardial infarction compared with
a 1 in 3 risk in men, the risks in women of stroke and heart
failure were 1 in 8 and 1 in 12, respectively, compared with 1
in 12 and 1 in 13, respectively, in men. These differences may
reflect the notably greater systolic blood pressure (a powerful
risk factor for stroke) and cardiothoracic ratio (a powerful
risk factor for heart failure and atrial fibrillation) in women
at baseline.
Why do women have a better survival than men? One
explanation is that a higher proportion of women who are
‘‘Rose positive’’ for angina do not have cardiac disease.18 28 29
Alternatively, women with definite angina and coronary
heart disease have better left ventricular systolic function
than men (although they have as much heart failure).30 Left
ventricular systolic function is a very powerful predictor of
death.
As described by others previously (and alluded to above),
we found ischaemic changes on the ECG to be a powerful
predictor of coronary death.7 25 In addition, we found that
these changes were also strong predictors of non-fatal
Table 3 Proportion of patients admitted to hospital for a cardiovascular cause (principal discharge diagnosis) over 20 years,
according to the presence of angina and ischaemic change on electrocardiogram at baseline
Men Women
No angina,
no ischaemic
changes
on ECG
(n = 5834)
No angina,
ischaemic
changes
on ECG
(n = 545)
Angina,
no ischaemic
changes
on ECG
(n = 517)
Angina,
ischaemic
changes
on ECG
(n = 152)
No angina,
no ischaemic
changes
on ECG
(n = 6961)
No angina,
ischaemic
changes
on ECG
(n = 594)
Angina,
no ischaemic
changes
on ECG
(n = 681)
Angina,
ischaemic
changes
on ECG
(n = 118)
Any
cardiovascular
cause
1859 (31.9) 230 (42.2)*** 219 (42.4)*** 72 (47.4)*** 1647 (23.7) 211 (35.5)*** 237 (34.8)*** 62 (52.5)***
1.00 1.57 (1.37 to
1.81)
1.40 (1.21 to
1.62)
2.40 (1.88 to
3.07)
1.00 1.45 (1.25 to
1.68)
1.38 (1.20 to
1.59)
2.54 (1.96 to
3.29)
Coronary heart
disease
821 (14.1) 113 (20.7)*** 117 (22.6)*** 37 (24.3)*** 557 (8.0) 83 (14.0)*** 110 (16.2)*** 24 (20.3)***
1.00 1.78 (1.46 to
2.18)
1.72 (1.40 to
2.10)
2.51 (1.77 to
3.54)
1.00 1.65 (1.30 to
2.09)
1.76 (1.42 to
2.18)
2.13 (1.40 to
3.26)
Myocardial
infarction
652 (11.2) 79 (14.5)* 86 (16.6)*** 32 (21.1)*** 393 (5.6) 61 (10.3)*** 78 (11.5)*** 18 (15.4)***
1.00 1.50 (1.18 to
1.91)
1.57 (1.24 to
1.98)
2.79 (1.92 to
4.06)
1.00 1.66 (1.67 to
2.19)
1.78 (1.89 to
2.29)
2.36 (1.45 to
3.85)
Heart failure 227 (3.9) 40 (7.3)*** 33 (6.4)** 15 (9.9)*** 177 (2.5) 51 (8.6)*** 47 (6.9)*** 13 (11.0)***
1.00 2.01 (1.42 to
2.83)
1.34 (0.92 to
1.96)
3.48 (2.03 to
5.98)
1.00 2.80 (2.03 to
3.87)
2.11 (1.51 to
3.00)
3.89 (2.18 to
6.94)
Atrial fibrillation 60 (1.0) 7 (1.3) 12 (2.3)** 0 (0) 65 (0.9) 11 (1.9)* 20 (2.9)*** 1 (0.8)
1.00 1.51 (0.68 to
3.34)
2.24 (1.15 to
4.34)
— 1.00 1.92 (0.99 to
3.69)
2.92 (1.73 to
4.92)
1.00 (0.14 to
7.33)
Stroke 371 (6.4) 54 (9.9)** 35 (6.8) 12 (7.9) 423 (6.1) 59 (9.9)*** 61 (9.0)** 14 (11.9)*
1.00 1.57 (1.17 to
2.10)
0.93 (0.65 to
1.33)
1.75 (0.97 to
3.14)
1.00 1.27 (0.95 to
1.69)
1.30 (0.98 to
1.71)
1.87 (1.08 to
3.22)
Aortic aneurysm 54 (0.9) 6 (1.1) 4 (0.8) 4 (2.6) 13 (0.2) 0 (0) 1 (0.1) 1 (0.8)
1.00 1.33 (0.56 to
3.14)
0.76 (0.27 to
2.17)
4.67 (1.60 to
13.57)
1.00 — 0.71 (0.09 to
5.47)
5.45 (0.67 to
44.30)
Venous
thromboembolism
102 (1.7) 10 (1.8) 9 (1.7) 2 (1.3) 72 (1.0) 6 (1.0) 10 (1.5) 1 (0.8)
1.00 1.33 (0.69 to
2.58)
1.08 (0.54 to
2.18)
1.40 (0.34 to
5.78)
1.00 0.98 (0.42 to
2.27)
1.12(0.56 to
2.21)
0.76 (0.10 to
5.59)
ECG, electrocardiogram.
Values are n (%) or adjusted HR (95% CI).
*p,0.05; **p,0.01; ***p,0.001 for the proportion of hospitalisations in each group compared with the group with no angina and no ischaemic change on ECG.
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coronary events and of other non-fatal and fatal cardiovas-
cular events such as heart failure and stroke. Indeed, an
abnormality on the ECG was a more powerful predictor of all
these adverse outcomes than the symptom of angina alone
(ie, in the absence of ischaemic changes on the ECG). People
with both an abnormality on the ECG and angina had the
worst outcome, with a risk of 1 in 2 for myocardial infarction
and 1 in 10 for stroke and heart failure in men and
corresponding values of 1 in 3, 1 in 5 and 1 in 8 in women.
Indeed, .75% of men and .66% of women in this category
experienced a major fatal or non-fatal cardiovascular event
during follow-up.
It should be emphasised that angina without associated
changes on an ECG (similar to uncomplicated angina in prior
studies2 6–8) was still predictive of a poor outcome, even in
women. However, as in the overall cohort, the risk of death
due to coronary disease in these patients was increased to a
greater extent in men (71%) than in women (33%), whereas
this difference was less for death from cardiovascular causes
(46% in men and 31% in women). We also found much less
difference between men and women when combined fatal
and non-fatal outcomes were considered, with an approxi-
mately 70–80% increase in risk of coronary events and a 40–
50% increase in risk of cardiovascular events in both sexes in
this category (ie, those with angina but without changes on
ECG).
Our study has several limitations. Angina was documented
at only one time point and spontaneous variation is well
recognised.27 31 The validity of the Rose Questionnaire and
which Rose categories should be included have been
debated.32–34 Our study was conducted in an area with a high
prevalence of coronary heart disease.35 We did not measure
morbidity (eg, symptoms or functional limitation) not
associated with hospital admission.27 Nor did we have records
of coronary revascularisation either as an outcome or a
treatment; similarly, we had no access to information on
medical treatment. The prevalence of angina increases with
increasing age36; however, by design, our study looks at
outcome in a group of middle-aged people. A lack of
applicability to other populations is possible, as this is a
cohort from Scotland and because the inception of the cohort
occurred 30 years ago. By necessity, this is a historical cohort,
demographics and risk factor profiles have changed in the
time interval, and it could not benefit from several recent
treatments that reduce morbidity and mortality in patients
with angina.37–40 The mortality of those with angina in our
study is higher than that reported in contemporary pharma-
ceutical trials. For example, the Prevention of Events with
Angiotensin Converting Enzyme Inhibition (PEACE) trial
reported 8.1% mortality at 5 years,41 and in the ACTION trial
(A Coronary disease Trial Investigating Outcome with
Nifedipine GITS) the mortality was 1.53 per 100 patient-
years42 (Renfrew–Paisley angina cohort: 5-year mortality
11.6% and 2.62 per 100 patient-years). The mean age of
patients was higher in both these studies (about 63 v 56 years
in our study). Contemporary pharmacological treatments and
revascularisation options may have improved outcome in
patients with angina.
In summary, angina, as identified by the Rose
Questionnaire, is common and is associated with substantial
long-term mortality and morbidity in both men and women.
Consideration of only death (or death and myocardial
infarction) greatly underestimates the public health burden
related to angina. Regarding middle-aged patients with
angina, almost two thirds of the men and half of the women
will die or require hospital admission for a cardiovascular
reason over the subsequent 20 years. If these people have
ischaemic changes on ECG, the proportions rise to more than
three quarters for men and two thirds for women. Vigorous
efforts to identify and treat patients with angina (many of
which, especially women,43 are not known to the healthcare
system4 44) could lead to substantial reductions in the direct
and indirect burden of cardiovascular disease.45 46
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